Orthopedic surgeons are increasingly asked about adipose-derived stem cells, and recent state legislation in Florida and Wyoming has sharpened interest in how a banking service might fit a practice. This guide gives the operational picture: what those laws actually do, what the musculoskeletal evidence honestly shows, how a harvest integrates into existing procedures, and the compliance steps that come before a first banking patient.
TLDR: Florida SB 1768 and Wyoming SF 48 are sometimes cited as regulatory tailwinds, but both govern physicians administering stem cell therapy, not the separate activity of banking a patient’s own tissue for preservation. Florida limits permitted therapy to orthopedics, wound care, and pain management from accredited facilities, and credible analyses read its permitted sources as excluding adipose-derived cells, a point any practice must confirm with counsel. The musculoskeletal evidence is early, and the ADIPOA2 trial of autologous adipose cells in knee osteoarthritis did not outperform placebo. No adipose-derived product holds FDA approval for any orthopedic condition. Banking preserves a patient’s own tissue under 21 CFR Part 1271; it is not a treatment and guarantees no eligibility, access, or clinical benefit.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease, including orthopedic or musculoskeletal conditions. No adipose-derived stem cell product currently has FDA approval for any orthopedic indication. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
The questions orthopedic surgeons raise are practical, and the honest answers require separating preservation from therapy and reading the law carefully. The sections below lay out the regulatory landscape, the evidence, the workflow, and the prerequisites without overstating what banking offers.
State Law Scope for Orthopedic Surgeons: FL and WY Compared
The first thing to establish is that both statutes regulate the administration of non-FDA-approved stem cell therapy, which is a different activity from banking a patient’s own tissue for future use. Banking is preservation. Administering therapy is a clinical act these laws address. Conflating the two is the most common error in this area, and it matters for compliance.
Florida Statutes Section 458.3245, effective July 1, 2025, permits a physician to administer non-FDA-approved stem cell therapy only when the use is within the physician’s scope and relates to orthopedics, wound care, or pain management. The cells must come from a facility that is FDA-registered and accredited by a recognized body, with a post-thaw viability report. Notably, the statute’s definition of permitted products excludes secreted or extracted human products such as cell factors, and credible legal and industry analyses read the law as excluding adipose-derived mesenchymal stem cells as a permitted therapy source. That interpretation is significant for any orthopedic practice considering adipose-related therapy and must be confirmed with qualified counsel.
Wyoming SF 48, the Stem Cell Freedom Act, was signed into law and takes effect July 1, 2026, amending Wyoming Statutes Section 33-26-202(b). Unlike Florida, it is built around autologous cells, meaning a patient’s own tissue, and its framework expressly contemplates cells derived from fat. It requires a physician-patient relationship, physician registration with the state board of medicine, and written informed consent.
| Feature | Florida SB 1768 (s. 458.3245) | Wyoming SF 48 (W.S. 33-26-202(b)) |
|---|---|---|
| Effective | July 1, 2025 | July 1, 2026 |
| Regulates | Administering non-FDA-approved therapy | Recommending and performing non-FDA-approved therapy |
| Indications | Orthopedics, wound care, pain management | Built around autologous use, not a fixed condition list |
| Cell source | Accredited-facility sourcing; adipose-derived cells read by credible analyses as excluded | Autologous cells, expressly including adipose-derived |
| Core requirements | Accredited sourcing, post-thaw viability report, advertising notice, signed consent | Physician registration, informed consent, physician-patient relationship |
| Relationship to banking | Governs therapy, not banking | Governs therapy, not banking |
For a practice-level summary of the rules that apply to providers, the overview of orthopedic physician rules and the SB 1768 checklist provide additional detail. Neither law converts banking into a therapy pathway, and neither should be presented to patients as doing so.
What the Musculoskeletal Trial Pipeline Actually Shows
An honest read of the musculoskeletal evidence is essential for any surgeon weighing this area. Adipose-derived cells have been studied in knee osteoarthritis and related conditions, but the results to date counsel caution rather than enthusiasm. The field is early, and registration of a study is not evidence of efficacy.
The most instructive example is the ADIPOA2 trial, a multicenter, double-blind, placebo-controlled Phase 2b study of autologous adipose-derived mesenchymal stromal cells in mild-to-moderate knee osteoarthritis, registered as NCT02838069. In its published results, the adipose-cell injection was not more effective than saline placebo on the primary outcome at six months. That is a negative result, and it deserves to be reported as one. For the broader science, the overview of adipose cells in orthopedics summarizes the research landscape.
The takeaway is that no adipose-derived product holds FDA approval for any orthopedic condition, and the most prominent controlled trial did not show superiority over placebo. Any patient conversation should reflect that reality plainly.
Integrating Harvest Into Existing Orthopedic Procedures
For surgeons who already perform procedures involving adipose access, a banking harvest can be coordinated within an existing surgical workflow, with collection handled under proper conditions and documented carefully. The harvest for banking is a collection step whose purpose is preservation, not preparation of a therapeutic product, and it should be described that way to staff and patients.
The provider-facing overview of the harvest procedure outlines how collection, handling, and transfer are structured. The practical considerations are scheduling the collection appropriately, maintaining sterile technique, and ensuring the tissue is transferred to the processing and storage partner under documented chain-of-custody. None of this requires the practice to administer any therapy.
Consent and Documentation Requirements
Banking requires its own separate, specific informed consent, distinct from consent for any surgical procedure the patient is undergoing. The consent should make clear that banking is a preservation service, that it is not a treatment, and that it does not guarantee eligibility for any future therapy, trial, or program. Documentation should record that the patient was counseled accordingly.
The service operates under the federal framework for human cells and tissues in 21 CFR Part 1271, which governs screening, handling, and storage. A practice should retain documentation of the banking partner’s regulatory status and of the consent obtained, and should keep banking records separate from records of clinical care.
The Five Compliance Prerequisites Before Your First Banking Patient
Before banking a first patient, an orthopedic practice can confirm five prerequisites:
- Legal confirmation of scope. Obtain counsel’s confirmation of how state law applies to the practice, including the distinction between banking and administering therapy and, in Florida, the permitted-source question for adipose-derived cells.
- Separate banking consent. Implement a specific informed-consent document for tissue banking that states banking is preservation, not treatment, and guarantees no future access or benefit.
- Documented harvest workflow. Establish a collection process with sterile technique and a documented chain-of-custody for transfer to the processing and storage partner.
- Verified partner regulatory status. Confirm and retain documentation that the banking partner operates under 21 CFR Part 1271 for screening, processing, and storage.
- Compliant patient communication. Ensure all patient-facing language avoids implying treatment and states that no adipose-derived product is FDA-approved for orthopedic conditions.
The overview of why physicians add banking describes how the service fits a practice once these prerequisites are met.
Physician Action Checklist
A condensed action list for an orthopedic practice:
- Confirm with counsel how Florida or Wyoming law applies, and document the banking-versus-therapy distinction.
- Adopt separate, specific banking consent that disclaims treatment and any guarantee of benefit.
- Stand up a documented harvest and chain-of-custody workflow.
- Verify and retain the banking partner’s 21 CFR Part 1271 regulatory status.
- Audit all patient-facing materials for compliant, non-promissory language.
Frequently Asked Questions
Does Florida SB 1768 authorize adipose banking?
No. SB 1768 governs physicians administering non-FDA-approved stem cell therapy for orthopedics, wound care, or pain management, not banking, which is a separate preservation activity. Credible analyses also read the statute as excluding adipose-derived cells as a permitted therapy source, which counsel should confirm.
Is there an FDA-approved adipose stem cell therapy for orthopedic conditions?
No. Adipose-derived cells have been studied in conditions such as knee osteoarthritis, but no adipose-derived product holds FDA approval for any orthopedic indication, and the ADIPOA2 trial did not show superiority over placebo.
Does banking require administering any therapy?
No. Banking is collection and preservation of a patient’s own tissue. It does not involve administering any therapy, and it should not be presented as a treatment.
What does Wyoming SF 48 change for orthopedic surgeons?
It establishes a state framework, effective July 1, 2026, for physicians performing autologous stem cell therapy, including from adipose tissue, with registration and consent requirements. It regulates therapy administration, not banking, and applies to Wyoming-licensed physicians acting within its terms.
How is adipose tissue banking regulated?
Banked adipose tissue is handled under 21 CFR Part 1271, the federal framework governing screening, processing, and storage of human cells and tissues.
Key Takeaways
For orthopedic surgeons, the integration question turns on a clear distinction and an honest reading of the evidence. Florida SB 1768 and Wyoming SF 48 govern administering stem cell therapy, not banking a patient’s own tissue for preservation, and Florida limits permitted therapy to orthopedics, wound care, and pain management while credible analyses read its permitted sources as excluding adipose-derived cells, a point requiring legal confirmation. The musculoskeletal evidence is early, and the ADIPOA2 trial of autologous adipose cells in knee osteoarthritis did not outperform placebo, with no adipose-derived product holding FDA approval for any orthopedic condition. A harvest can be integrated into an existing surgical workflow, but only with separate banking consent, documented chain-of-custody, and a verified partner operating under 21 CFR Part 1271. Above all, banking adipose tissue is a preservation service for potential future use; it is not a treatment, and it does not guarantee eligibility, access, or clinical benefit.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Orthopedic practices evaluating whether to add a preservation service can review the service model and contact the team to discuss integration and documentation requirements.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including orthopedic surgery input is required before publication. Please consult your orthopedic surgeon before making any decisions about treatment or research participation.
Related guide: the physician resource center.
